At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ODD ODDITY Tech Ltd.
Trading 01-30 15:51:11 EST
32.87
-0.76
-2.26%
High34.01Low32.77Vol337.73K
Open33.66D1 Closing33.63Amplitude3.69%
Mkt Cap1.89BTradable Cap1.27BTotal Shares57.44M
T/O11.19MT/O Rate0.87%Tradable Shares38.70M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
GlobeNewswire  ·  01-29 20:05
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
GlobeNewswire  ·  01-28 21:45
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
Radiopharm Theranostics Says Cash And Cash Equivalents Of Approximately $34.52m For Or The 6 Months Ended December 31, 2025 Provide Runway Into 2027
Benzinga  ·  01-28 20:09
Radiopharm Theranostics Says Cash And Cash Equivalents Of Approximately $34.52m For Or The 6 Months Ended December 31, 2025 Provide Runway Into 2027
Press Release: Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
Dow Jones  ·  01-28 20:00
Press Release: Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
Odd Burger Warns of Imminent Cease Trade Order Over Delayed Annual Filings
TIPRANKS  ·  01-28 06:13
Odd Burger Warns of Imminent Cease Trade Order Over Delayed Annual Filings
Quoin announces submission to Japanese MHLW for ODD for QRX003
TIPRANKS  ·  01-27
Quoin announces submission to Japanese MHLW for ODD for QRX003
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
GlobeNewswire  ·  01-27
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
LEADS BIOLABS-B (09887): Vilisin™ Granted Orphan Drug Designation (ODD) by European Commission for Treatment of Extrapulmonary Neuroendocrine Carcinoma
Stock News  ·  01-22
LEADS BIOLABS-B (09887): Vilisin™ Granted Orphan Drug Designation (ODD) by European Commission for Treatment of Extrapulmonary Neuroendocrine Carcinoma
Dyne announces MHLW in Japan granted ODD for zeleciment basivarsen
TIPRANKS  ·  01-20
Dyne announces MHLW in Japan granted ODD for zeleciment basivarsen
Insider-Favored Growth Stocks To Consider In January 2026
Simply Wall St.  ·  01-20
Insider-Favored Growth Stocks To Consider In January 2026
Assessing Oddity Tech (ODD) Valuation After Analyst Praise And METHODIQ Skincare Launch
Simply Wall St.  ·  01-17
Assessing Oddity Tech (ODD) Valuation After Analyst Praise And METHODIQ Skincare Launch
Odd Burger Delays Annual Filings After Financing Default Triggers Liquidity Crunch
TIPRANKS  ·  01-16
Odd Burger Delays Annual Filings After Financing Default Triggers Liquidity Crunch
ODDITY Tech Secures Expanded $350 Million Credit Facilities to Fund Growth
TIPRANKS  ·  01-13
ODDITY Tech Secures Expanded $350 Million Credit Facilities to Fund Growth
Oddity Tech Ltd: Co Has Entered Into Amendments to Existing Agreements With Syndicate of Banks to Secure Credit Facilities for Total of $350 Mln
THOMSON REUTERS  ·  01-13
Oddity Tech Ltd: Co Has Entered Into Amendments to Existing Agreements With Syndicate of Banks to Secure Credit Facilities for Total of $350 Mln
Oddity Tech Secures $350 Million Credit Facility to Boost Growth and Flexibility
Reuters  ·  01-13
Oddity Tech Secures $350 Million Credit Facility to Boost Growth and Flexibility
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor
GlobeNewswire  ·  01-12
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor
Is It Time To Reassess Oddity Tech (ODD) After Recent Share Price Weakness?
Simply Wall St.  ·  01-08
Is It Time To Reassess Oddity Tech (ODD) After Recent Share Price Weakness?
ODDITY Tech Is Maintained at Overweight by Keybanc
Dow Jones  ·  01-08
ODDITY Tech Is Maintained at Overweight by Keybanc
KeyBanc Reaffirms Their Buy Rating on ODDITY Tech Ltd. Class A (ODD)
TIPRANKS  ·  01-08
KeyBanc Reaffirms Their Buy Rating on ODDITY Tech Ltd. Class A (ODD)
Oddity Tech Ltd. Chief Science Officer Departs
Reuters  ·  01-08
Oddity Tech Ltd. Chief Science Officer Departs

Introduction

Company Name.
ODDITY Tech Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Oddity Tech Ltd. operates as a consumer tech company that builds and scales digital-first brands to disrupt beauty and wellness industries. The company serves consumers worldwide through its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. It owns IL MAKIAGE and SpoiledChild brands. The company was incorporated in 2013 and is headquartered in Tel Aviv, Israel with additional office in New York, New York.
Issue price:
--